Seattle-based has announced a $120 million grant from the to further strengthen the (CVIA).
Established in 2016 with $11 million in funding from the Gates Foundation, CVIA works across the entire vaccine development and delivery spectrum, with a focus on low-resource settings. To help advance that mission, the organization recently welcomed four experts to its leadership team. They are Fred Cassels, global head, Enteric and Diarrheal Diseases, who served as chief of the Enteric and Hepatic Diseases Branch at the ; Bruce Innis, global head, Respiratory Infections and Maternal Immunization, who most recently served as vice president and senior vaccine development leader for Influenza and Dengue Vaccines at GlaxoSmithKline and previously served as chief of the Department of Virus Diseases at the ; Harshvardhan (Hersh) Mehta, global head, Development (Chemistry, Manufacturing, and Controls, who has served in senior roles at Merck, Sanofi, MedImmune, and Roche; and Karen Midthun, global head, Regulatory, who served as director of the 's Center for Biologics Evaluation and Research.
PATH veterans taking on new roles to round out the CVIA leadership team include Deborah Atherly, global head, Policy, Access, & Introduction; Ashley Birkett, global head, Malaria Vaccines; Jorge Flores, global head, Clinical; John Konz, global head, Integrated Portfolio & Financial Management; Jessica Milman, managing director, CVIA; and Katya Spielberg, global head, Finance & Contract Management.
"We are excited to continue our long-standing partnership with the Bill & Melinda Gates Foundation to develop and introduce vaccines for the families and communities that need them most," said Steve Davis, president and CEO of PATH. "We are working on vaccines against over a dozen deadly diseases and partnering with governments and companies around the world to save lives and improve health through vaccine innovation and immunization."